0000899243-21-042710.txt : 20211103 0000899243-21-042710.hdr.sgml : 20211103 20211103162018 ACCESSION NUMBER: 0000899243-21-042710 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211026 FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SV7 Impact Medicine Fund LP CENTRAL INDEX KEY: 0001780602 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40925 FILM NUMBER: 211375690 BUSINESS ADDRESS: STREET 1: 71 KINGSWAY CITY: LONDON STATE: X0 ZIP: WC2B 6ST BUSINESS PHONE: 44 20 7421 7081 MAIL ADDRESS: STREET 1: 71 KINGSWAY CITY: LONDON STATE: X0 ZIP: WC2B 6ST REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SV7 (IMF) GP LLP CENTRAL INDEX KEY: 0001889859 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40925 FILM NUMBER: 211375689 BUSINESS ADDRESS: STREET 1: 71 KINGSWAY CITY: LONDON STATE: X0 ZIP: WC2B 6ST BUSINESS PHONE: 44 20 7421 7081 MAIL ADDRESS: STREET 1: 71 KINGSWAY CITY: LONDON STATE: X0 ZIP: WC2B 6ST ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xilio Therapeutics, Inc. CENTRAL INDEX KEY: 0001840233 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851623397 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-833-1027 MAIL ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-10-26 2021-10-28 1 0001840233 Xilio Therapeutics, Inc. XLO 0001780602 SV7 Impact Medicine Fund LP 71 KINGSWAY LONDON X0 WC2B 6ST UNITED KINGDOM 0 0 1 0 0001889859 SV7 (IMF) GP LLP 71 KINGSWAY LONDON X0 WC2B 6ST UNITED KINGDOM 0 0 1 0 Common Stock 2021-10-26 4 C 0 998544 A 998544 D Common Stock 2021-10-26 4 C 0 998544 A 998544 I See footnote Common Stock 2021-10-26 4 C 0 302588 A 1301132 D Common Stock 2021-10-26 4 C 0 302588 A 1301132 I See footnote Common Stock 2021-10-26 4 P 0 312500 16.00 A 1613632 D Common Stock 2021-10-26 4 P 0 312500 16.00 A 1613632 I See footnote Series B Convertible Preferred Stock 2021-10-26 4 C 0 9486166 0.00 D Common Stock 998544 0 D Series B Convertible Preferred Stock 2021-10-26 4 C 0 9486166 0.00 D Common Stock 998544 0 I See footnote Series C Convertible Preferred Stock 2021-10-26 4 C 0 2874595 0.00 D Common Stock 302588 0 D Series C Convertible Preferred Stock 2021-10-26 4 C 0 2874595 0.00 D Common Stock 302588 0 I See footnote The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Xilio Therapeutics, Inc. Common Stock on a 0.1053-for-1 basis and had no expiration date. Reflects a 1-for-9.5 reverse stock split which became effective October 15, 2021. Consists of shares of Common Stock held by SV7 Impact Medicine Fund LP, via its general partner, SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of Xilio's board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to the shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. This Form 4 has been amended to include 312,500 shares of Common Stock purchased by SV7 Impact Medicine Fund LP in connection with Xilio's initial public offering. /s/ Kathleen R. Henry, pursuant to Power of Attorney for SV7 Impact Medicine Fund LP 2021-11-03 /s/ Kathleen R. Henry, pursuant to Power of Attorney for SV7 (IMF) GP LLP 2021-11-03